- Home
- HMST vs TLSA Comparison
HMST vs TLSA Comparison
Compare HMST & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- TLSA
- Stock Information
- Founded
- HMST 1921
- TLSA 2013
- Country
- HMST United States
- TLSA United Kingdom
- Employees
- HMST N/A
- TLSA N/A
- Industry
- HMST Major Banks
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- TLSA Health Care
- Exchange
- HMST Nasdaq
- TLSA Nasdaq
- Market Cap
- HMST 211.3M
- TLSA 175.3M
- IPO Year
- HMST 2012
- TLSA 2000
- Fundamental
- Price
- HMST $13.03
- TLSA $1.36
- Analyst Decision
- HMST Hold
- TLSA
- Analyst Count
- HMST 3
- TLSA 0
- Target Price
- HMST $14.17
- TLSA N/A
- AVG Volume (30 Days)
- HMST 77.5K
- TLSA 475.2K
- Earning Date
- HMST 07-28-2025
- TLSA 06-10-2025
- Dividend Yield
- HMST N/A
- TLSA N/A
- EPS Growth
- HMST N/A
- TLSA N/A
- EPS
- HMST N/A
- TLSA N/A
- Revenue
- HMST $78,454,000.00
- TLSA N/A
- Revenue This Year
- HMST $161.80
- TLSA N/A
- Revenue Next Year
- HMST $8.90
- TLSA N/A
- P/E Ratio
- HMST N/A
- TLSA N/A
- Revenue Growth
- HMST N/A
- TLSA N/A
- 52 Week Low
- HMST $8.09
- TLSA $0.63
- 52 Week High
- HMST $16.10
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- HMST 65.81
- TLSA 49.39
- Support Level
- HMST $12.18
- TLSA $1.34
- Resistance Level
- HMST $12.76
- TLSA $1.68
- Average True Range (ATR)
- HMST 0.49
- TLSA 0.17
- MACD
- HMST 0.01
- TLSA -0.02
- Stochastic Oscillator
- HMST 92.42
- TLSA 13.04
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.